600645.SH
中源协和
SSE · Healthcare · Biotechnology · CN
CNY 19.23
−3.99%Year over year
Reported trailing growth
- Revenue
- -7.6%
- EBITDA
- —
- EBIT
- +54.8%
- EPS
- +28.8%
- Free cash flow
- -1.5%
- Operating cash flow
- -4.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -2.2%
- EBITDA
- +5.4%
- EBIT
- +4.4%
- Net income
- +0.2%
- EPS
- +1.4%
- Free cash flow
- +17.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026